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Abstract
The human brain has no lymphatic system, but produces over a half-liter each day of cerebrospinal fluid. The
cerebrospinal fluid is secreted at the choroid plexus and occupies the cavities of the four ventricles, as well as the
cranial and spinal sub-arachnoid space. The cerebrospinal fluid moves over the surfaces of the brain and spinal
cord and is rapidly absorbed into the general circulation. The choroid plexus forms the blood-cerebrospinal fluid
barrier, and this barrier is functionally distinct from the brain microvascular endothelium, which forms the blood-
brain barrier. Virtually all non-cellular substances in blood distribute into cerebrospinal fluid, and drug entry into
cerebrospinal fluid is not an index of drug transport across the blood-brain barrier. Drug injected into the
cerebrospinal fluid rapidly moves into the blood via bulk flow, but penetrates into brain tissue poorly owing to the
limitations of diffusion. Drug transport into cerebrospinal fluid vs. brain interstitial fluid requires knowledge of the
relative expression of transporters at the choroid plexus versus the brain microvascular endothelium.
Introduction
One hundred years ago, the prevailing view was that
nutrients in blood were transferred to brain not via the
vascular system, but rather via cerebrospinal fluid (CSF).
This idea emerged from studies with vital dyes, which
were acidic such as trypan blue, and the acidic dyes did
not penetrate the vasculature, which forms the blood-
brain barrier (BBB). It was not until the 1930s, when
studies with basic vital dyes, which do cross the vascula-
ture, demonstrated the importance of the vascular route
to brain. Nevertheless, the misconceptions of a hundred
years ago are alive and well today. Virtually all neurolo-
gists, academic neuroscientists, and industry scientists
believe that drug entry into CSF is a measure of drug
penetration through the BBB. It is also widely believed
that the trans-cranial delivery of drug to the CSF com-
partment is a viable solution to the brain drug delivery
problem.
There are two barrier systems in brain: the BBB,
which is formed by the brain microvascular endothe-
lium, and the blood-CSF barrier, which is formed by the
choroid plexus epithelium. In addition, the arachnoid
epithelium forms a barrier around the brain creating the
sub-arachnoid space. Drug transport from blood to CSF
is regulated by the choroid plexus, or blood-CSF barrier.
Drug transport from blood to interstitial fluid (ISF) is
regulated by the brain microvascular endothelium, or
BBB. In order to delineate the relative roles of the chor-
oid plexus and the BBB in limiting drug transport in the
brain, it is useful to consider the quantitative aspects of
CSF flow within the 1200 g human brain.
Anatomical considerations
There is approximately 140 mL of CSF in the human
brain [1], which fills the four ventricles (20 mL), spinal
sub-arachnoid space (30 mL), and the cranial sub-ara-
chnoid space (90 mL). The CSF volume in rat brain is
approximately 90 μL [2]. In the human brain, the entire
CSF volume is produced and excreted to blood every
4-5 hours or 4-5 times per day. CSF is secreted by the
choroid plexus epithelium and passes from the lateral
ventricles to the third ventricle to the fourth ventricle to
the cranial and spinal subarachnoid spaces, and finally
the CSF is absorbed into superior sagittal sinus of the
peripheral bloodstream across the arachnoid villi. The
estimated surface area of the human choroid plexus is
approximately 0.021 m
2 [3], which is many-fold less
than the surface area of the brain capillary endothelium
which forms the BBB. With respect to the vasculature of
brain, there are > 100 billion capillaries in the human
brain comprising a total length of approximately
400 miles. Yet, the intra-endothelial volume is quite
small, about 1 uL/g brain. Thus, the volume of the
capillary intracellular space in brain is about 1 uL for
the rat brain, and about 1 mL for the human brain. The Correspondence: wpardridge@mednet.ucla.edu
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inter-capillary distance in brain is about 40 μm, which is
space for 2 neurons. Thus, every neuron in the brain is
perfused by its own blood vessel. Diffusion across a dis-
tance of 20 μm is instantaneous, even for a large mole-
cule. Once the drug or solute crosses the vascular
barrier from blood there is immediate equilibration
throughout the entire brain extravascular volume.
Drug entry into CSF is not a measure of BBB permeability
Drug entry into the CSF compartment from blood
should not be taken as an index of drug transport
across the BBB. Drug transfer from blood to CSF
occurs across the choroid plexus, which is leaky com-
pared to the BBB. Virtually all small and large mole-
c u l e si nb l o o dp e n e t r a t ei n t oC S F ,a tar a t ei n v e r s e l y
related to the molecular weight of the substance. The
finding of drug entry into CSF is expected, and does
not discriminate between those drugs that do, and do
not, cross the BBB. This is because the choroid plexus,
which regulates drug transfer into CSF from blood,
and the brain capillary endothelium, which regulates
drug transfer into ISF from blood, are comprised of
completely different epithelial/endothelial barriers. The
application of recent proteomics technology will enable
the description of the different transporter expression
profiles in the BBB and choroid plexus [4]. The differ-
ence between drug transfer across the choroid plexus
and across the BBB is illustrated in the case of azi-
dothymidine (AZT). This drug is rapidly transported
across the choroid plexus epithelium and rapidly enters
the CSF compartment in humans [5]. However, there
is negligible transport of AZT across the BBB in vivo,
owing to active efflux transport processes at the brain
microvasculature [6].
Drug injection into the CSF is a slow intravenous infusion
Drug that is injected into the CSF compartment is
rapidly transported out of brain to the blood. Following
the ICV injection of drug, it moves through the CSF
flow tracks, and is absorbed into the peripheral blood-
stream across the arachnoid villi to enter the general
circulation. This is illustrated by barbiturate studies in
the dog. The dose of barbiturate that causes anesthesia
in the dog is the same, whether the drug is given by an
intravenous or intra-cerebroventricular (ICV) route [7].
The barbiturate injected into the CSF exits the brain,
rapidly enters the peripheral blood, and then re-enters
the brain across the BBB to induce anesthesia, similar to
the pathway taken by drug injected intravenously. The
ICV administration of cholecystokinin (CCK) decreases
feeding behavior, not via a central mechanism within
the brain, but rather due to entry of the neuropeptide
into the peripheral bloodstream and activation of CCK
receptors in peripheral tissues [8]. Christy and Fishman
[9] noted 50 years ago in studies of CSF transport of
cortisol in the dog that, “a CSF injection is like a slow
intravenous infusion.”
Drug penetration into brain parenchyma from CSF is
minimal
When drug is injected into the CSF compartment, the
drug exits this space relatively rapidly via convection
and bulk flow through the CSF flow tracts. Conversely,
the entry of drug into brain parenchyma from the CSF
compartment is mediated by diffusion, a process that is
much slower than CSF convection and bulk flow. More-
over, diffusion decreases exponentially with the distance.
It takes four days for albumin to diffuse 5 mm through
water [10]. During four days, the entire CSF volume has
turned over about 20 times. The effective diffusion dis-
tance in the brain is decreased with binding of the drug
to brain cell surfaces, efflux across the BBB, and meta-
bolism of the drug. If the concentration of drug is mea-
sured at each mm of brain parenchyma removed from
the ependymal surface surrounding the ventricular CSF,
one finds that the drug concentration in brain parench-
yma decreases logarithmically as the distance from the
CSF surface is increased [11]. The maximum penetra-
tion of a relatively inert small molecule such as hydro-
xyurea into the brain is 2 mm, whereas the maximal
penetration of a biologically active neuropeptide such as
brain-derived neurotrophic factor (BDNF) is only
0.3 mm [12]. The concentration of a small molecule
such as 1,3-bis(2-chloroethyl-1-nitroso-urea) (BCNU) in
brain parenchyma removed just 1 mm from the CSF
s u r f a c ei so n l y1 %o ft h eB C N Uc o n c e n t r a t i o ni nt h e
CSF compartment [13]. In practice, most investigators
do not measure drug concentration in brain at 1 or 2
mm from the CSF compartment, but rather measure
drug concentration in the entire brain parenchyma ipsi-
lateral to the CSF injection. When this is done, it is dif-
ficult to measure any increase in the concentration of
the drug in brain of rats or monkeys [14,15], because
the drug rapidly exits the CSF to the general circulation
following an ICV injection.
CSF administration exposes the ependymal surface
to high drug concentrations
Since the penetration of drug into brain decreases
exponentially with the distance from the CSF surface
[11], it is necessary to administer high concentrations
of drug into the CSF compartment. The ependymal
surface is exposed to very high drug concentrations,
which can have toxic side effects. The ICV administra-
tion of nerve growth factor (NGF) resulted in axonal
sprouting and Schwann cell hyperplasia on the ependy-
mal or arachnoid surface [16]. The ICV administration
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ventricular astrogliosis [17]. The ICV administration of
glial-derived neurotrophic factor (GDNF) in Parkin-
son’s disease, resulted in no penetration of the neuro-
peptide into the substantia nigra or into the caudate
putamen nucleus, but did result in a high incidence of
adverse events [18]. Conversely, it is sometimes desir-
able to deliver high concentrations of drug to the
meningeal surface of the brain, such as in the treat-
ment of meningeal infiltration of leukemia cells,
and this can be achieved with intrathecal drug
administration.
The CSF “microcirculation”
The CSF ‘macrocirculation’ involves production of the
CSF within the ventricles, bulk flow through the sub-
arachnoid space, and absorption into the arachnoid
villi. However, along this route there is a CSF ‘micro-
circulation’ that originates from the pial surface of
the brain [19]. There is evidence for solute movement
from CSF to brain parenchyma via transport through
the Virchow-Robin spaces surrounding the penetrat-
ing arteries at the pial surface. From there, CSF com-
ponents may move along the basement membrane of
parenchymal capillaries via a process of bulk flow dri-
ven by the pulsations of penetrating arteries in the
brain. The CSF microcirculation provides a pathway
for solute movement from CSF to deep spaces within
brain parenchyma. However, the CSF microcirculation
is not a quantitatively important pathway for drug
distribution into the brain from the CSF compart-
ment. This is because the rate of bulk flow of fluid
through the Virchow-Robin spaces from the pial sur-
face is slow compared to the rapid rate of bulk flow
through the CSF macrocirculation. The rate of bulk
flow of CSF via the macrocirculation is 520 and 2 μL/
min per whole brain in humans and rats, respectively
[2]. The rate of CSF bulk flow via the macrocircula-
tion is approximately 20-fold greater than the rate of
bulk flow through the parenchyma via the microcircu-
lation, which is approximately 0.1 μL/min in the
rat [20].
The CSF macrocirculation functions as a closed
hydraulic system, which provides a mechanical buffer
between the skull and the brain, and relieves the effects
of gravitational and accelerational stresses [21]. Without
the CSF system, the brain could not function and brain
abnormalities follow from either the under- or over-pro-
duction of CSF. Since the entire CSF volume is turned
over 4-5 times each day, it is crucial that the choroid
plexus epithelial transport processes that underlie the
production of CSF be tightly regulated. A greater under-
standing of this regulation will arise from the elucida-
tion of the molecular and cellular biology of solute
transporters at both the apical and basolateral mem-
branes of the choroid plexus epithelial cell.
Conclusions
Drug entry into CSF from blood is expected for all
drugs, irrespective of whether the drug crosses the BBB.
The finding of drug penetration into the CSF should
not be taken as evidence that the drug crosses the BBB.
Drug injected into the CSF compartment is rapidly
exported to the blood with minimal penetration of brain
parenchyma more than 1-2 mm from the ependymal
surface of brain.
Authors’ contributions
Sole author and had read and approved the final version of the manuscript.
Competing interests
The author is consultant to ArmaGen Technologies, Inc.
Received: 6 December 2010 Accepted: 18 January 2011
Published: 18 January 2011
References
1. Oldendorf WH: Cerebrospinal fluid formation and circulation. Prog Nuc
Med 1972, 1:336-358.
2. Davson H: The Cerebrospinal Fluid. Handbook of Neurochemistry 1969,
2:23-48.
3. Dohrmann GJ: The choroid plexus: a historical review. Brain Res 1970,
18:197-218.
4. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y,
Uchida Y, Ito S, Terasaki T: Quantitative atlas of membrane transporter
proteins: development and application of a highly sensitive
simultaneous LC/MS/MS method combined with novel in-silico peptide
selection criteria. Pharm Res 2008, 25:1469-1483.
5. Yarchoan R, Broder S: Development of antiretroviral therapy for the
acquired immunodeficiency syndrome and related disorders. N Engl J
Med 1987, 316:557-564.
6. Dykstra KH, Arya A, Arriola DM, Bungay PM, Morrison PF, Dedrick RL:
Microdialysis study of zidovudine (AZT) transport in rat brain.
J Pharmacol Exp Ther 1993, 267:1227-1236.
7. Aird RB: A study of intrathecal, cerebrospinal fluid-to-brain exchange. Exp
Neurol 1984, 86:342-358.
8. Crawley JN, Fiske SM, Durieux C, Derrien M, Roques BP: Centrally
administered cholecystokinin suppresses feeding through a peripheral-
type receptor mechanism. J Pharmacol Exp Ther 1991, 257:1076-1080.
9. Christy NP, Fishman RA: Studies of the blood-cerebrospinal fluid barrier
to cortisol in the dog. J Clin Invest 1961, 40:1997-2006.
10. Pardridge WM: Peptide Drug Delivery to the Brain New York: Raven Press;
1991.
11. Blasberg RG, Patlak C, Fenstermacher JD: Intrathecal chemotherapy: brain
tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther
1975, 195:73-83.
12. Mak M, Fung L, Strasser JF, Saltzman WM: Distribution of drugs following
controlled delivery to the brain interstitium. J Neurooncol 1995, 26:91-102.
13. Fung LK, Shin M, Tyler B, Brem H, Saltzman WM: Chemotherapeutic drugs
released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-
nitrosourea in the rat brain. Pharm Res 1996, 13:671-682.
14. Billiau H, Heremans D, Ververken J, van Damme H, Carton P, de Somer :
Tissue distribution of human interferons after exogenous administration
in rabbits, monkeys, and mice. Arch Virol 1981, 68:19-25.
15. Baskin DG, Woods SC, West DB, van Houten M, Posner BI, Dorsa DM,
Porte D: Immunocytochemical detection of insulin in rat hypothalamus
and its possible uptake from cerebrospinal fluid. Endocrinology 1983,
113:1818-1825.
16. Day-Lollini PA, Stewart GR, Taylor MJ, Johnson RM, Chellman GJ:
Hyperplastic changes within the leptomeninges of the rat and monkey
Pardridge Fluids and Barriers of the CNS 2011, 8:7
http://www.fluidsbarrierscns.com/content/8/1/7
Page 3 of 4in response to chronic intracerebroventricular infusion of nerve growth
factor. Exp Neurol 1997, 145:24-37.
17. Yamada K, Kinoshita A, Kohmura E, Sakaguchi T, Taguchi J, Kataoka K,
Hayakawa T: Basic fibroblast growth factor prevents thalamic
degeneration after cortical infarction. J Cereb Blood Flow Metab 1991,
11:472-478.
18. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Lozano AM,
Penn RD, Simpson RK, Stacy M, Wooten GF: Randomized, double-blind
trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology
2003, 60:69-73.
19. Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA: Evidence for
a ‘paravascular’ fluid circulation in the mammalian central nervous
system, provided by the rapid distribution of tracer protein throughout
the brain from the subarachnoid space. Brain Res 1985, 326:47-63.
20. Szentistvanyi I, Patlak CS, Ellis RA, Cserr HF: Drainage of interstitial fluid
from different regions of rat brain. Am J Physiol 1984, 246:F835-F844.
21. Oldendorf WH: Why is cerebrospinal fluid? Bulletin of the Los Angeles
Neurological Society 1967, 32:169-180.
doi:10.1186/2045-8118-8-7
Cite this article as: Pardridge: Drug transport in brain via the
cerebrospinal fluid. Fluids and Barriers of the CNS 2011 8:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pardridge Fluids and Barriers of the CNS 2011, 8:7
http://www.fluidsbarrierscns.com/content/8/1/7
Page 4 of 4